Trump's Psychedelic Executive Order: The Instrument Reveals the Purpose

On Saturday, President Trump signed an executive order directing federal agencies to accelerate access to psychedelic drugs for mental health treatment. Joe Rogan stood behind the Resolute Desk. Marcus Luttrell, the Navy SEAL whose Afghanistan memoir became "Lone Survivor," told the president he'd save lives. FDA Commissioner Marty Makary announced¹ that three psychedelic compounds would receive priority review vouchers next week. The scene was designed to feel like a breakthrough. I think we should look more carefully at what's actually breaking through.

The emotional case is simple and powerful: veterans are dying. The VA's 2025 National Veteran Suicide Prevention Annual Report³ puts the number at 17.5 veteran suicides per day in 2023, slightly down from 17.6 in 2022. That's roughly 6,400 per year. Sixty-one percent of those who died weren't even receiving VA care. Standard treatments for PTSD — SSRIs, cognitive behavioral therapy — fail 30-40% of patients with treatment-resistant forms. MDMA-assisted therapy showed a 67% remission rate in its Phase 3 trials, published in Nature Medicine in 2021. That's a real number describing real suffering meeting a treatment that appears genuinely promising. Nobody serious disputes the urgency.

But urgency can be weaponized. And the specific instruments this executive order deploys don't match the problem it claims to solve.

Start with the FDA's actual objection to MDMA. In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee voted 9-2 against MDMA's effectiveness⁴ for PTSD, and 10-1 that its benefits didn't outweigh risks. This wasn't bureaucratic foot-dragging. The committee raised specific scientific concerns: functional unblinding (participants could tell they'd received MDMA because of its obvious psychoactive effects), inadequate assessment of functional impairment, missing safety data on abuse potential and liver toxicity⁵, and credible allegations of therapist misconduct during trials. A peer-reviewed analysis in the Journal of Psychopharmacology⁶ argued the committee may have lacked appropriate frameworks to evaluate a drug-therapy combination, but also acknowledged that some MAPS/Lykos trial criticisms were valid "regardless of the paradigmatic framework."

Now look at what the executive order actually does. According to the White House fact sheet², it directs the FDA to issue priority review vouchers, instructs the Attorney General to initiate rescheduling reviews upon Phase 3 completion, extends Right to Try pathways to psychedelics including ibogaine, and allocates $50 million through ARPA-H for state-level matching funds. These are primarily commercial and scheduling instruments. None of them resolve the functional unblinding problem. None of them fund the improved trial designs the FDA specifically requested. None create a REMS framework (the mandatory in-clinic supervision and monitoring structure that accompanied esketamine's approval in 2019). The mismatch between the stated problem — veterans need access to a promising therapy — and the chosen tools — scheduling pressure and commercial fast-tracking — is the tell.

Consider the most direct alternative: expanded compassionate use at existing trial sites. The FDA already granted an Expanded Access IND for MDMA²³ in 2021, while it remained Schedule I. MAPS conducted its entire Phase 3 trial program under Schedule I restrictions. The VA is already participating in at least five psychedelic trials⁸ in New York, California, and Oregon. An executive order could have directed the VA to massively expand compassionate use enrollment at those sites, putting the treatment in veterans' hands faster than any rescheduling timeline. That instrument was available. It was not chosen.

What was chosen instead reads like a menu designed for pharmaceutical and venture capital positioning. Compass Pathways immediately issued a press release⁹ commending the order, with CEO Kabir Nath calling it an alignment of "regulatory urgency with patient need." This is the same company that holds broad patents on synthetic psilocybin (COMP360)¹⁰ backed by Peter Thiel and Christian Angermayer, whose patent claims have been criticized by researchers¹¹ at the Usona Institute, the Heffter Research Institute, and in a Cornell Law Review analysis¹² as attempts to monopolize a naturally occurring compound. The Patent Trial and Appeal Board upheld Compass's core patents¹³ in 2022, and one patent attorney called the outcome "complete wins for Compass, on every issue raised." If psilocybin gets rescheduled and the FDA approval pathway accelerates, Compass's IP position gives it first-mover advantage in a market where patents protect COMP360's formulation through 2040²².

There's an ironic history here. Last October, as Psychedelic Alpha reported¹⁴, the White House actually vetoed FDA's inclusion of Compass Pathways in its inaugural priority voucher list. Now, months later, the executive order reverses that veto and institutionalizes the voucher pathway. What changed? Not the science. The political calculation.

The ibogaine inclusion is the most revealing element. Trump specifically named ibogaine in the signing ceremony. FDA Commissioner Makary announced IND clearance for ibogaine¹⁴, meaning clinical trials can now begin. But ibogaine has a documented cardiotoxicity profile that makes the MDMA blinding debate look quaint. A 2023 review found 58 ibogaine-associated emergencies, including 38 deaths¹⁵. NIH funded research in the 1990s but discontinued it due to "cardiovascular toxicity."⁷ Johns Hopkins researcher Frederick Barrett told PBS that "it's been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity." The existing human evidence base consists largely of uncontrolled observational studies with no placebo groups. A physician writing about the order¹⁶ put it bluntly: the executive order "addresses the knowledge gap, not the safety gap."

I want to be clear about what I'm not saying. I'm not saying psychedelic therapy is bunk. The MDMA data, while methodologically challenged, shows a signal that deserves rigorous pursuit. The psilocybin research is genuinely exciting. I also accept that FDA timelines can be frustratingly slow, and that the esketamine precedent — approved in 2019 despite its own functional unblinding concerns¹⁷, albeit with mandatory REMS oversight — creates legitimate questions about whether MDMA is being held to an inconsistent standard.

But the strongest counterargument — that veterans are dying while bureaucracy stalls — actually proves my point when you follow it to its conclusion. If veteran access were truly the operative priority, the fastest pathway would be expanding VA compassionate use at existing sites, not corporate patent-aligned rescheduling. The Right to Try pathway the order invokes has a documented track record of underperformance: bioethicists writing in JAMA¹⁸ and elsewhere noted it does not require manufacturers to provide drugs, insurers to cover them, or adverse events to be systematically reported. The Goldwater Institute, the libertarian think tank that championed Right to Try¹⁹, has always been more interested in dismantling FDA authority than in patient outcomes.

The pattern here is structurally identical to the 2018 Right to Try Act: genuine patient suffering provides the emotional justification for a policy mechanism that primarily creates regulatory shortcuts for commercially positioned actors. Veterans are real. Their suffering is real. But they are being used as the moral shield for a deregulatory template whose primary beneficiaries are holding Nasdaq-listed shares.

What to watch next: (1) Whether the three priority review vouchers issued next week go to companies with major VC and pharma backing or to nonprofit entities like the former MAPS. (2) Whether the VA simultaneously expands compassionate use enrollment, or whether scheduling reform becomes the only instrument deployed. (3) Whether Compass Pathways' patent position consolidates or faces new challenges as psilocybin moves toward approval. If the vouchers go exclusively to commercial entities, compassionate use doesn't expand, and Compass's market position strengthens — that will confirm the executive order is a market-opening mechanism dressed in veteran camouflage. I expect all three.